Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study

BACKGROUND: Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular dis...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Am Heart Assoc
Prif Awduron: Zhao, Di, Guallar, Eliseo, Vaidya, Dhananjay, Ndumele, Chiadi E., Ouyang, Pamela, Post, Wendy S., Lima, Joao A., Ying, Wendy, Kass, David A., Hoogeveen, Ron C., Shah, Sanjiv J., Subramanya, Vinita, Michos, Erin D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033823/
https://ncbi.nlm.nih.gov/pubmed/31928156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013966
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg